Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) saw a large decrease in short interest in June. As of June 15th, there was short interest totalling 1,710,000 shares, a decrease of 5.5% from the May 31st total of 1,810,000 shares. Based on an average daily trading volume, of 302,500 shares, the days-to-cover ratio is currently 5.7 days.
Actinium Pharmaceuticals Trading Up 4.6 %
ATNM opened at $7.28 on Thursday. The firm has a market capitalization of $216.80 million, a price-to-earnings ratio of -4.26 and a beta of 0.20. Actinium Pharmaceuticals has a twelve month low of $4.00 and a twelve month high of $10.24.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Free Report) last announced its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. Research analysts predict that Actinium Pharmaceuticals will post -1.57 earnings per share for the current year.
Institutional Trading of Actinium Pharmaceuticals
Analysts Set New Price Targets
ATNM has been the subject of a number of analyst reports. Stephens began coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, June 17th. Maxim Group lifted their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. Finally, StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, May 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Actinium Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $25.60.
View Our Latest Stock Analysis on Actinium Pharmaceuticals
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
Further Reading
- Five stocks we like better than Actinium Pharmaceuticals
- How to Invest in Biotech Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Consumer Staples Stocks, Explained
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- How Can Investors Benefit From After-Hours Trading
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.